The Basel Years: How a Pharmaceutical Company Handled a Sacred Drug

“The manufacturer distributed LSD to researchers worldwide at minimal cost from 1947 to 1966. This was pharmaceutical generosity without precedent. What it meant about the manufacturer's understanding of what it had synthesized is worth examining.”

In 1947, the Basel drug company released LSD under a trade name, as tablets and an injectable solution, as a tool for psychiatric research. The pricing was minimal: the manufacturer supplied LSD to qualified researchers at essentially no cost, treating it as a contribution to science rather than a commercial product.

This decision shaped everything that followed. Because LSD was freely available to researchers, the 1947-1966 period produced over 1,000 scientific papers, treated approximately 40,000 patients in clinical programs, and established a research base that, despite the 1968 scheduling, could not be fully erased. The knowledge existed in published form.

Hofmann's memoir reveals his ambivalence about this period. He was proud of LSD's research applications and troubled by its counterculture appropriation. He understood that the manufacturer's generous distribution had enabled both.

In 1963, under pressure from the US Food and Drug Administration, the manufacturer began restricting distribution, requiring institutional affiliation and research protocols. In 1966, facing the US Congressional hearings on LSD and the wave of negative publicity driven by Leary's public advocacy, the manufacturer withdrew its LSD product from the market entirely and ceased distribution.

The withdrawal ended the clinical research program. It also ended the period in which a pharmaceutical company had voluntarily restrained commercial impulses in the belief that a substance required special handling. Hofmann consistently praised this restraint. He argued that LSD needed to be treated as a sacred drug, carefully, with appropriate protocols, without commercialization, and that the company had, for nearly twenty years, honored this requirement.

The contrast with the current psychedelic industry is stark. Dozens of companies have built commercial pipelines around psychedelic compounds. The manufacturer's model, provide it freely, don't commercialize it, restrict access to qualified researchers, has no analog in the 2020s landscape. Whether this represents necessary adaptation to regulatory reality or a failure of the field's founding values is a question Hofmann's memoir raises implicitly throughout.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Lee & Shlain, Acid Dreams (1985)
• Stevens, Storming Heaven (1987)